FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062477137> ?p ?o ?g. }

• W2062477137 endingPage "S153" @default.
• W2062477137 startingPage "S153" @default.
• W2062477137 abstract "To assess the feasibility and acute toxicity of full-dose chemotherapy and accelerated hypofractionated radiation therapy in inoperable locally advanced non-small-cell lung cancer using helical Tomotherapy, maintaining the dose to the organs at risk (BED2 Gy) below the values of conventional radiation therapy. Between January 2009 and October 2011, 18 patients were enrolled to receive 2 cycles of induction chemotherapy (Cisplatin 75 mg/m2 day1 every 21 days combined with Docetaxel 75 mg/m2 day 1 every 21 days), accelerated hypofractionated radiation therapy and 2 further cycles of consolidation chemotherapy (IRST Protocol 162.01). Patients had pathologically documented stage IIIA (19%) or IIIB (81%) non-small-cell lung cancer and all had undergone CT and CT/PET scans for staging and restaging after treatment. Bronchoscopy was performed before induction chemotherapy and after radiation therapy to evaluate local disease status. With regard to radiation therapy, a multiphase chest free breathing CT-simulation scan with administration of contrast agents was performed in all cases. To simulate internal organ motion, volumes of interest (VOI) were defined to cover the VOI in all of the non-fused phases. The dose prescription was always 30 Gy/5 daily fractions at the reference isodose (60-70%) with an increasing dose inhomogeneity of up to 40 Gy inside the tumor. The dose prescription for the lymph node volume was always 25 Gy/5 daily fractions at the reference isodose, with an increasing dose inhomogeneity of up to 37.5 Gy in the clinically involved lymph nodes. The organs at risk (OAR) dose did not normally exceed normal tissue tolerance limits. Acute toxicity was recorded using the RTOG scale. Median follow-up was 20 months. Overall survival at 22 months was 55%. Local progression-free and distant metastasis-free survival was 56% and 58%, respectively. Grade 3/4 radiation therapy toxicity was not observed. One patient underwent surgery, obtaining a complete pathological response. Our preliminary data demonstrate the feasibility of a week-long treatment using accelerated hypofractionated radiation therapy, whilst maintaining a dose similar to the OAR or even lower than that of conventional treatments in inoperable locally advanced lung cancer. This ongoing study underlines the possibility of administering accelerated hypofractionation for central primary tumor volumes (T3, T4) and for mediastinal lymph node stations without severe side-effects. More follow-up data are needed." @default.
• W2062477137 created "2016-06-24" @default.
• W2062477137 creator A5001169395 @default.
• W2062477137 creator A5001267679 @default.
• W2062477137 creator A5006051342 @default.
• W2062477137 creator A5017022820 @default.
• W2062477137 creator A5018482016 @default.
• W2062477137 creator A5032402792 @default.
• W2062477137 creator A5043696566 @default.
• W2062477137 creator A5057910692 @default.
• W2062477137 creator A5063507440 @default.
• W2062477137 creator A5082059913 @default.
• W2062477137 date "2012-11-01" @default.
• W2062477137 modified "2023-10-16" @default.
• W2062477137 title "Accelerated Hypofractionated Radiation Therapy Using Tomotherapy Plus Chemotherapy for Inoperable Locally Advanced Lung Cancer: Preliminary Results From a Prospective Phase II Trial" @default.
• W2062477137 doi "https://doi.org/10.1016/j.ijrobp.2012.07.395" @default.
• W2062477137 hasPublicationYear "2012" @default.
• W2062477137 type Work @default.
• W2062477137 sameAs 2062477137 @default.
• W2062477137 citedByCount "0" @default.
• W2062477137 crossrefType "journal-article" @default.
• W2062477137 hasAuthorship W2062477137A5001169395 @default.
• W2062477137 hasAuthorship W2062477137A5001267679 @default.
• W2062477137 hasAuthorship W2062477137A5006051342 @default.
• W2062477137 hasAuthorship W2062477137A5017022820 @default.
• W2062477137 hasAuthorship W2062477137A5018482016 @default.
• W2062477137 hasAuthorship W2062477137A5032402792 @default.
• W2062477137 hasAuthorship W2062477137A5043696566 @default.
• W2062477137 hasAuthorship W2062477137A5057910692 @default.
• W2062477137 hasAuthorship W2062477137A5063507440 @default.
• W2062477137 hasAuthorship W2062477137A5082059913 @default.
• W2062477137 hasBestOaLocation W20624771371 @default.
• W2062477137 hasConcept C121608353 @default.
• W2062477137 hasConcept C126322002 @default.
• W2062477137 hasConcept C126838900 @default.
• W2062477137 hasConcept C141071460 @default.
• W2062477137 hasConcept C143998085 @default.
• W2062477137 hasConcept C155806632 @default.
• W2062477137 hasConcept C2776256026 @default.
• W2062477137 hasConcept C2776694085 @default.
• W2062477137 hasConcept C2776713427 @default.
• W2062477137 hasConcept C2781190966 @default.
• W2062477137 hasConcept C2989005 @default.
• W2062477137 hasConcept C509974204 @default.
• W2062477137 hasConcept C71924100 @default.
• W2062477137 hasConceptScore W2062477137C121608353 @default.
• W2062477137 hasConceptScore W2062477137C126322002 @default.
• W2062477137 hasConceptScore W2062477137C126838900 @default.
• W2062477137 hasConceptScore W2062477137C141071460 @default.
• W2062477137 hasConceptScore W2062477137C143998085 @default.
• W2062477137 hasConceptScore W2062477137C155806632 @default.
• W2062477137 hasConceptScore W2062477137C2776256026 @default.
• W2062477137 hasConceptScore W2062477137C2776694085 @default.
• W2062477137 hasConceptScore W2062477137C2776713427 @default.
• W2062477137 hasConceptScore W2062477137C2781190966 @default.
• W2062477137 hasConceptScore W2062477137C2989005 @default.
• W2062477137 hasConceptScore W2062477137C509974204 @default.
• W2062477137 hasConceptScore W2062477137C71924100 @default.
• W2062477137 hasIssue "3" @default.
• W2062477137 hasLocation W20624771371 @default.
• W2062477137 hasOpenAccess W2062477137 @default.
• W2062477137 hasPrimaryLocation W20624771371 @default.
• W2062477137 hasRelatedWork W1972682189 @default.
• W2062477137 hasRelatedWork W1975025425 @default.
• W2062477137 hasRelatedWork W2005957375 @default.
• W2062477137 hasRelatedWork W2034576500 @default.
• W2062477137 hasRelatedWork W2074966133 @default.
• W2062477137 hasRelatedWork W2085307618 @default.
• W2062477137 hasRelatedWork W2155647244 @default.
• W2062477137 hasRelatedWork W2357406576 @default.
• W2062477137 hasRelatedWork W4382279650 @default.
• W2062477137 hasRelatedWork W1899415052 @default.
• W2062477137 hasVolume "84" @default.
• W2062477137 isParatext "false" @default.
• W2062477137 isRetracted "false" @default.
• W2062477137 magId "2062477137" @default.
• W2062477137 workType "article" @default.